Clinical trials generate promising results for improving kidney health
The results of numerous high-impact Phase III clinical trials that could affect kidney-related medical care were presented in person at American Society of Nephrology Kidney Week 2026, Oct. 22–25.
Clinical trials have yielded promising outcomes for enhancing kidney health. Atacicept, a medication that targets two cytokines involved in IgA nephropathy, was found to significantly reduce urinary protein levels in the ORIGIN 3 trial. The drug received accelerated approval after FDA review, with a safety profile comparable to placebo. Following two years of follow-up, atacicept continued to demonstrate kidney protection and a marked reduction in disease progression.
Another promising treatment is sibeprenlimab, which inhibits the cytokine APRIL. In the VISIONARY trial, sibeprenlimab reduced the risk of serious kidney function loss or failure by 97% compared to placebo. The drug was associated with stable kidney function over two years, making it a potential game-changer for patients with IgA nephropathy, a condition often diagnosed at a young age and linked to a significant lifetime risk of kidney failure.
Furthermore, the dual inhibition of cytokines BLyS and APRIL with telitacicept in the TELIGAN trial showed that the medication slows kidney function loss and substantially reduces the risk of kidney failure in high-risk IgA nephropathy patients. Both atacicept and telitacicept have shown favorable safety profiles, preserving kidney function and slowing disease progression in phase III trials.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
